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miR-21Left ventricular (LV) pressure overload is a major cause of heart failure. Transforming growth factors-β (TGF-βs)
promote LV remodeling under biomechanical stress. BAMBI (BMP and activin membrane-bound inhibitor) is a
pseudoreceptor that negatively modulates TGF-β signaling. The present study tests the hypothesis that BAMBI
plays a protective role during the adverse LV remodeling under pressure overload. The subjects of the study
were BAMBI knockout mice (BAMBI−/−) undergoing transverse aortic constriction (TAC) and patients with se-
vere aortic stenosis (AS). We examined LV gene and protein expression of remodeling-related elements, histo-
logical ﬁbrosis, and heart morphology and function. LV expression of BAMBI was increased in AS patients and
TAC-mice and correlateddirectlywith TGF-β. BAMBI deletion led to a gain ofmyocardial TGF-β signaling through
canonical (Smads) and non-canonical (TAK1–p38 and TAK1–JNK) pathways. As a consequence, the remodeling
response to pressure overload in BAMBI−/− mice was exacerbated in terms of hypertrophy, chamber dilation,
deterioration of long-axis LV systolic function and diastolic dysfunction. Functional remodeling associated tran-
scriptional activation of ﬁbrosis-related TGF-β targets, up-regulation of the proﬁbrotic micro-RNA-21, histolog-
ical ﬁbrosis and increased metalloproteinase-2 activity. Histological remodeling in BAMBI−/− mice involved
TGF-βs. BAMBI deletion in primary cardiac ﬁbroblasts exacerbated TGF-β-induced proﬁbrotic responses while
BAMBI overexpression in NIH-3T3 ﬁbroblasts attenuated them. Our ﬁndings identify BAMBI as a critical negative
modulator of myocardial remodeling under pressure overload. We suggest that BAMBI is involved in negative
feedback loops that restrain the TGF-β remodeling signals to protect the pressure-overloaded myocardium
from uncontrolled extracellular matrix deposition in humans and mice.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Degenerative aortic valve stenosis (AS) and hypertension have be-
come the most common cardiovascular diseases after coronary disease
in developed countries with an increasing worldwide prevalence con-
comitant with aging of the populations. The chronic left ventricular
(LV) pressure overload condition produced by such pathologies triggersmuscle actin; BAMBI, BMP and
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rights reserved.severe LV structural modiﬁcations, including cardiomyocyte hypertro-
phy and interstitial ﬁbrosis [1], which are deleterious over time and re-
sult in progressive increases in LV stiffness, diastolic and systolic
dysfunction and heart failure [2]. Aortic valve replacement, which is
currently the only accepted treatment for AS, frequently fails to reverse
the LV maladaptive remodeling [3]. Likewise, regression of the LV re-
modeling under antihypertensive treatment only seldom correlates
with the degree of blood pressure reduction [4]. The persistence of ei-
ther diffusemyocardial interstitial ﬁbrosis or LV hypertrophy after ther-
apeutic intervention predicts poorer short- and long-term survival and
functional postoperative status in AS patients [5] and is a strong inde-
pendent predictor of adverse cardiovascular outcomes in the hyperten-
sive population [6]. Understanding the mechanisms governing the
myocardial response to biomechanical stress is crucial to develop ther-
apeutic strategies aimed at slowing disease progression and favoring
the regression of the adverse pressure overload remodeling.
Transforming growth factors-β (TGF-βs) are key players in the LV re-
modeling response to pressure overload [7] in animal models [8] and in
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overexpression causes ﬁbroblast proliferation and transdifferentiation
into myoﬁbroblasts [12], endothelial-to-mesenchymal transition [13],
and hypertrophic growth of cardiomyocytes [14],which collectively con-
tribute to the progression of cardiac ﬁbrosis and hypertrophy. TGF-βs in-
duce these pleiotropic cellular responses by interactingwith the receptor
complexes of two types of serine/threonine kinase receptors referred to
as types I and II, which trigger the phosphorylation of receptor-regulated
Smad (R-Smad) proteins. Phosphorylated R-Smads bind to Smad4, and
the complexesmove into the nucleus, where they regulate transcription
[15]. Several downstreammediators of the TGF-β pathway are involved
in the adverse myocardial remodeling induced by pressure overload.
The TGF-β proﬁbrogenic signals best analyzed in rodentmodels areme-
diated by the canonical transcription factors Smad2 and Smad3 [16,17].
The roles of the non-canonical, mitogen-activated protein kinase
(MAPK) pathways, including TGFβ-activated kinase 1 (TAK1) and its
downstream kinases p38 and c-Jun N-terminal kinase (JNK) are less
well understood [18–20].
MicroRNAs (miRNAs) are small noncoding RNA, which function as
post-transcriptional regulators of gene expression. miRNAs play a
central role in diverse cellular processes, including proliferation, dif-
ferentiation, and death. The last decade has revealed microRNA-21
(miR-21) as a new mediator of TGF-β1-induced ﬁbrosis [21]. In ro-
dent models of pressure overload, miR-21 acts downstream of
TGF-β to modulate several features of the myocardial ﬁbrotic process
[22,23]. A recent report from our group also supports such a relevant
role for miR-21 in AS patients [24].
The cellular response elicited by TGF-βs is tightly controlled by
multiple mechanisms at each step in their signaling pathway [25].
BAMBI (BMP and activin membrane-bound inhibitor) is a transmem-
brane glycoprotein structurally related to the TGF-β type I receptors,
but it lacks the intracellular kinase domain. BAMBI functions as a
decoy type I receptor that antagonizes TGF-β-family signals by
preventing the formation of active receptor complexes upon ligand
binding [26]. Little is known about the physiological functions regu-
lated by BAMBI or the pathological consequences of an imbalance be-
tween BAMBI and TGF-β signaling. Recent reports indicate that
aberrant BAMBI expression plays a critical role in the pathophysiology
of inﬂammatory [27] and ﬁbrotic processes [28] and in cancer develop-
ment [29,30]. Here, we demonstrate that BAMBI plays a modulator role
in TGF-β-induced proﬁbrogenic signals in the myocardium under bio-
mechanical stress inmice and AS patients.We propose that BAMBI pro-
tects the pressure overloaded myocardium against uncontrolled
extracellular matrix deposition through a negative feedback loop that
restrains TGF-β-mediated deleterious remodeling signals. Alterations
in BAMBImay play a role in the pathophysiology of myocardial ﬁbrosis,
and manipulation of BAMBI might confer disease-speciﬁc therapeutic
beneﬁts.2. Methods
2.1. Pressure overload studies in humans
During surgery, myocardial tru-cut needle biopsies (4–10 mg)
were obtained from the lateral LV wall from 45 individuals undergo-
ing cardiac surgery, including 30 patients with isolated severe AS and
a control group of 15 patients with pathologies producing no signiﬁ-
cant LV pressure or volume overload (atrial septal defect, aortic aneu-
rysm, and papillary ﬁbroelastoma). Patients with aortic or mitral
regurgitation greater than mild, major coronary stenosis greater
than 50%, previous cardiac operations, malignancies or poor renal or
hepatic function were ineligible for the study. The demographic and
clinical characteristics of the patients are shown in Supplemental
Table S1. The study followed the Declaration of Helsinki guidelines
for investigation on human subjects. The Institutional Ethics andClinical Research Committee approved the study, and all patients
gave written informed consent.
2.2. Pressure overload studies in mice
Adult (16–20 weeks old) female BAMBI-deﬁcient mice (BAMBI−/−)
in a C57BL/6 genetic background [31] were kindly provided by Dr. J.C.
Izpisua-Belmonte (The Salk Institute, La Jolla, CA). Wild type female
mice (C57BL/6) were used as controls. Mice were housed in a room
kept at 22 °C with 12:12 h light/dark cycle and provided with standard
food andwater ad libitum. The studywas approved by the University of
Cantabria Institutional Laboratory Animal Care and Use Committee (ap-
proval ID 2008/05) and conducted in accordance with the “European
Directive for the Protection of Vertebrate Animals Used for Experimen-
tal and Other Scientiﬁc Purposes” (European Communities Council Di-
rective 86/606/EEC). All efforts were made to minimize animal
suffering.
2.2.1. Transverse aortic constriction
LV pressure overload was induced by calibrated banding of the
aorta at the mid-transverse arch level (TAC), as described in Ref.
[32]. Brieﬂy, the mice were anesthetized by intraperitoneal injection
of ketamine (10 mg/kg) and xylazine (15 mg/kg). The surgery was
performed under spontaneous ventilation. The aorta was approached
extrapleurally and constricted at the mid-arch level with a 7/0 poly-
propylene ligature using a blunted 27-gauge (0.41-mm OD) needle
as a calibrator. This constriction induced a degree of geometric steno-
sis of approximately 65% in diameter. The mice were sham operated
or subjected to TAC for 1 or 4 weeks (n=5 to 9 per group). After
completion of the follow-up, the mice were euthanized, and the car-
diac mass was measured gravimetrically and indexed to the animal's
body weight. The LV samples were snap frozen in liquid nitrogen or
ﬁxed in 4% paraformaldehyde for histology.
For neutralizing antibody studies, a series of BAMBI+/+ and
BAMBI−/−micewere treated during the post-constriction follow-up pe-
riod with a pan-neutralizing monoclonal (1D11.16.8 clone) anti-TGF-β
antibody (TGF-β Ab) speciﬁc for all isoforms of murine TGF-β or with
a control isotype-matched IgG. The mice (n=4 per group) received
i.p. injections of TGF-β Ab or IgG1 at the dose of 0.5 mg every other day.
2.2.2. Echocardiographic measurements
Transthoracic echocardiography was performed with ultrasound
equipment [Agilent Sonos 5500 (Philips/Hewlett Packard) using
15-MHz linear and 12-MHz sectorial scanheads and Vevo-770
(VisualSonics, Toronto, ON, Canada) using a high-resolution trans-
ducer centered at 30 MHz]. Two dimensionally guided, short axis,
M-mode recordings of the LV were recorded by an operator blinded
to the study groups. Transcoarctation pressure gradients were mea-
sured using continuous wave Doppler analysis at the distal arch. LV
dimensions and wall thicknesses were measured following the rec-
ommendations of the American Society of Echocardiography. The mi-
tral annular plane systolic excursion (MAPSE) measurements were
obtained from four-chamber views using M-mode imaging. The pa-
rameters of diastolic LV function were obtained by pulsed-wave mi-
tral inﬂow analysis and tissue Doppler imaging to obtain the ratio of
passive inﬂow by pulsed-wave to tissue Doppler (E/E′). The following
parameters were derived from the recordings: heart rate, pressure
gradient across the arch constriction, LV end-diastolic (LVEDd) and
end-systolic (LVESd) internal diameters, interventricular septum
(IVST) and posterior wall (PBW) thicknesses. The LV ejection fraction
(LVEF) and mitral annular plane systolic excursion (MAPSE) were
used as indices of radial and longitudinal systolic functions, respec-
tively. The ratio of peak early transmitral ﬂow velocity (E) to peak
early myocardial tissue velocity (E′) was used as an index of LV ﬁlling
pressure. Cardiac mass, estimated echocardiographically or measured
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expressed in mg/g.2.3. Determination of remodeling-related mRNA and microRNA elements
in the LV by real-time quantitative PCR
Total RNA from the LVmyocardium and cultured cells was obtained
by TRIzol extraction (Invitrogen). MirRNA was isolated using a miRNA
isolation kit (mirVana, Ambion). The mRNA was reverse transcribed
using random primers with an RT-PCR kit (Fermentas). MiRNAs from
tissue and cells were reversed transcribed using speciﬁc primers for
miR-21 and RNU6-2 (Applied Biosystems). The cDNA products were
ampliﬁed by quantitative PCR (q-PCR) in a MX-3000P Stratagene
thermocycler.
The sequences of primers used for SYBR Green real-time PCRwere as
follows: collagen I (forward primer: 5′-tcctgctggtgagaaaggat-3′; reverse
primer: 5′-tccagcaataccctgaggtc-3′); and the housekeeping gene, ribo-
somal 18S (forward primer: 5′-gtaacccgttgaaccccatt-3′; reverse primer:
5′ccatccaatcggtagtaggg-3′). The speciﬁc TaqMan assays (Applied
Biosystems) used were miR-21, RNU6-2, TGF-β1, TGF-β2, TGF-β3,
Smad2, Smad3, Smad4, TAK1, BAMBI, collagen III α1 (Col III),
ﬁbronectin-1 (FN), α-smooth muscle actin (α-SMA) and 18S. The
expression levels of the myocardial genes were normalized to the
housekeeping gene, ribosomal 18S. Myocardial miR-21 expression
was normalized to the endogenous control, RNU6-2. Duplicate tran-
script levels were determined in a minimum of three independent
experiments.2.4. Immunodetection of LV remodeling-related proteins by Western blot
Thirty micrograms of total or nuclear protein extracts were resolved
on a 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel and
transferred onto polyvinylidene diﬂuoride (PVDF)membranes (Bio-Rad
Lab., California, USA) using a Mini Trans-Blot Electrophoresis Transfer
Cell (Bio-Rad Lab., California, USA). The primary antibodies were against
BAMBI (Abnova), ﬁbronectin-1 (Santa Cruz Biotechnology), p38 (Santa
Cruz Biotechnology), JNK1/3 (Santa Cruz Biotechnology), Smad4 (Cell
Signaling), GAPDH (Santa Cruz Biotechnology) and Rb (Santa Cruz Bio-
technology). After extensive washings in TBS-T (TBS+0.05% Tween
20), the membranes were incubated with peroxidase-conjugated sec-
ondary antibodies. Secondary antibodies were detected using the ECL
Advance kit (GE Healthcare Europe GmbH, Munich, Germany). Blot
quantiﬁcation was performed by densitometry using Scion Image
Software.2.5. Assessment of MMP activity in mouse LV by gelatin zymography
Detection of active forms of MMPs was assessed by zymography,
as described previously [33]. Samples for analysis were diluted into
a non-reducing SDS-buffer. Ten micrograms of proteins per lane
were separated by electrophoresis in 10% SDS-PAGE gel containing
1% gelatin. After running, the gel was renatured through incubation
in Triton X-100 (2.5% in 50 mM tris pH 7.4, 5 mM CaCl2 and 1 μM
ZnCl2) for 30 min with gentle shaking at room temperature. The gel
was rinsed and incubated overnight at 37 °C with developing buffer
(50 mM tris pH 7.4, 5 mM CaCl2 and 1 μM ZnCl2). The gel was stained
with 0.5% Coomassie Blue G250 (in 30% ethanol and 10% acetic acid)
for 30 min. Staining was stopped with 2% acetic acid. Zymographic
bands were scanned and the optical density was measured using
the ImageJ software. The problem bands were normalized to the con-
trol samples in the same gel and the data were expressed as relative
activity in fold increase. Silver staining of a strip obtained from the
bottom of the gel (below the 37 kDa marker) was used as loading
control.2.6. Histological assessment of myocardial ﬁbrosis
The hearts were ﬁxed in paraformaldehyde (3.7% in PBS, freshly
prepared) for 48 h and then embedded in parafﬁn. Four coronal sec-
tions (5 μm) at the level of the papillary muscles from each animal
(n=4) were stained using Masson's trichrome. Digital photographs
of the full LV sections were captured using a camera (Axiocam
MRc5, Zeiss) attached to a stereo-microscope (Zeiss Axiomat). In
each complete LV section, the proportion of the total ﬁbrosis area
was calculated by densitometric analysis (ImageJ software) as the
blue-stained areas divided by the total LV area. The operator was
blinded to the experimental group during the analysis.2.7. BAMBI immunostaining
2.7.1. Immunoﬂuorescence
After deep anesthesiawith amixture of xylazine and ketamine,mice
were perfused with heparinized saline for 1 min and ﬁxative solution
containing 4% paraformaldehyde in PBS for 15 min. After perfusion,
the heart was dissected out and post-ﬁxed for 12 h in the same solution
at 4 °C. The tissue blocks were washed in PBS, cryoprotected with 30%
sucrose at 4 °C until they sank, and stored at −80 °C. Seven microns
LV sections were cut on a cryostat and mounted on gelatin-subbed
slides.
Mouse LV squash preparations were prepared from small LV frag-
ments incubated in paraformaldehyde (4% in PBS, freshly prepared)
for 2 h and washed in PBS. Each tissue fragment was transferred to
a drop of PBS on a siliconized slide and squash preparations of disso-
ciated cardiomyocytes and ﬁbroblasts were performed as previously
reported in Ref. [34]. Then, the samples were sequentially treated
with 0.25% collagenase in PBS for 30 min at 37 °C and 0.5% Triton
X-100 in PBS for 30 min.
The primary cultures of cardiac ﬁbroblasts were ﬁxed with para-
formaldehyde for 15 min at room temperature. After extensive wash-
ing in PBS, the cells were permeabilized using 0.2% Triton X-100.
In all preparation types, nonspeciﬁc sites were blocked by incu-
bation with PBS containing 1% BSA and 0.3 M glycine for 60 min at
room temperature. After extensive washing, the samples were incu-
bated with the primary antibodies (1/50 in PBS) overnight, at 4 °C.
After washing in PBS, the samples were incubated with secondary
ﬂuorochrome-conjugated antibodies for 45 min at room tempera-
ture and washed and mounted in VectaShield (Vector Laboratories,
Burlingame, CA). We used primary antibodies against BAMBI
(Santa Cruz Biotechnology) and vimentin (Abcam). The speciﬁc sec-
ondary antibodies were conjugated with FITC (Jackson, USA) or Cy5
(Abcam). Dapi (Sigma) was used as a nuclear counterstain. Omis-
sion of the primary or secondary antibodies completely abolished
speciﬁc staining. Confocal microscopy was performed with an
LSM-510 laser scanning microscope (Carl Zeiss Inc., Germany)
using a 40× objective.2.7.2. Avidin–biotin complex (ABC) immunohistochemistry
BAMBI immunostaining was performed in 5 μm sections from
human LV samples ﬁxed in 4% paraformaldehyde and included in par-
afﬁn. Heat-induced antigen retrieval was performed in 10 mM citric
acid monohydrate (pH 6.0). Endogenous peroxidase was blocked
with 0.3% H2O2 for 30 min. Sections were incubated in the anti
BAMBI primary antibody (1/50 in PBS) overnight at 4 °C. After exten-
sivewashing, the sections were incubatedwith the biotinylated second-
ary antibody in PBS for 30 min followed by the complex of avidin–biotin
peroxidase (Vector ABC kit) and the chromogen diaminobenzidine. Be-
foremounting, the sections were counterstainedwith Harris hematoxy-
lin. Negative controls were performed using PBS instead of the primary
antibody.
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TGF-β1 in cultured NIH-3T3 ﬁbroblasts as measured by luciferase reporter
assays
The changes in collagen I and BAMBI transcription induced by re-
combinant TGF-β1 were assessed in NIH-3T3 ﬁbroblasts transiently
transfected with the collagen Iα1 or BAMBI promoter regions cloned
into the luciferase reporter pGL3 basic vector (pBAMBI-Luc was kindly
provided by Dr. Tetsu Akiyama, Institute of Molecular an d Cellular Bio-
science, Tokyo). The signaling effectors were determined by silencing
either Smad2/3 or TAK-1 with speciﬁc siRNAs (Santa Cruz Biotechnolo-
gy). The consequence of BAMBI overexpression on TGF-β1-induced col I
transcriptional activation was assessed in cells co-transfected with the
BAMBI open reading frame (BAMBI-ORF) (BAMBI-pFLCI; ImaGenes,
Berlin, Germany) and pCol-Luc.
The cells were cultivated in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 100 units/ml penicillin and 100 mg/ml streptomycin at 37 °C, in
5% CO2. The cellswere seeded onto 96well plates (2×104/well) and cul-
tured for 12 h. For the collagen I promoter luciferase reporter assays, the
cells were transiently transfected with the following: a) pCol-Luc
(50 ng); b) pCol-Luc (50 ng) plus Smad2/3 siRNA (10 nM) or control
scrambled siRNA; c) pCol-Luc (50 ng) plus TAK1 siRNA (10 nM) or con-
trol siRNA; and d) pCol-Luc (50 ng) plus BAMBI-ORF-pFLCI (0.4 μg/ml)
using FuGENE®6 transfection reagent (Roche Molecular Biochemicals).
After 8 h of incubation, increasing concentrations (0, 0.3, 0.6 and
1.5 ng/ml) of recombinant TGF-β1 (R&D Systems) were added to the
medium.
For the BAMBI promoter luciferase reporter assays, the cells were
transiently transfected with the following: a) pBAMBI-Luc promoter
(100 ng); b) pBAMBI-Luc (100 ng) plus Smad2/3 siRNA (10 nM) or
control scrambled siRNA and c) pBAMBI-Luc (100 ng) plus TAK1
siRNA (10 nM) or control scrambled siRNA using FuGENE®6 transfec-
tion reagent (Roche Molecular Biochemicals). After 8 h of incubation,
recombinant TGF-β1 (0, 0.3 and 0.6 ng/ml) was added to the
medium.
Twenty-four hours later, luciferase assays were performed using the
Luciferase® Reporter Assay System (Promega) following the manufac-
turer's protocol. Luciferase activities were expressed in relation to the
background activity of the empty pGL3-Basic or pFLCI vectors.
2.9. Effects of recombinant TGF-β1 onmaturemiR-21 expression in cultured
NIH-3T3 ﬁbroblasts
NIH-3T3 cells (1×106) were plated in 25 cm2 ﬂasks. Twenty-four
hours later, the cells were transiently transfected with 10 nM
pre-miR-21 or control miRNA using FuGENE®6 in the presence of in-
creasing concentrations of BAMBI-pFLCI (0, 0.2, 0.4 and 0.6 μg/ml) or
the empty pFLCI vector control. In a series of experiments, siSmad2/3,
siTAK-1 or scrambled siRNA were transfected. Four hours later, the
cells were incubated with recombinant TGF-β1 (0.3 ng/ml) for 24 h.
The cells were harvested, and the mRNA and micro-RNAs were puri-
ﬁed and retrotranscribed to perform q-PCR as described above.
2.10. Transcriptional changes induced by recombinant TGF-β1 in primary
cultures of mouse cardiac ﬁbroblasts
Neonatal cardiac ﬁbroblasts were isolated from C57BL/6 and
BAMBI−/− mice by enzymatic digestion. Brieﬂy, the ventricles were
excised, washed and minced in ice-cold PBS. The minced tissue was
then digested at 37 °C with an enzyme cocktail (10 mg trypsine,
5285 units collagenase, and 85,000 units DNAse) for 30 min. The su-
pernatants from these incubations were collected, centrifuged, and
resuspended in DMEM supplemented with 10% FBS, 10% donor bo-
vine serum (DBS), 100 units/ml penicillin and 100 mg/ml streptomy-
cin. For the experiments, low passage cells (p2) were seeded onto35-mm cell culture dishes and incubated at 37 °C and 5% CO2 for
15–20 h. The unattached cells were discarded, and the attached
cells were cultured until approximately 70% conﬂuent. The cells
were then growth arrested by incubation in DMEM containing 1%
FBS for 12 h. The ﬁbroblasts were treated for 6 h with recombinant
TGF-β1 (0.6 ng/ml) and harvested for further analysis.
2.11. Statistics
All the assays in mice were performed in a minimum of ﬁve individ-
uals per group (n=5 to 9). The experiments in cultured cells were
performed in triplicate and repeated on three separate occasions. Values
are reported asmeans±S.E.M. The GraphPad Prism 5.01 and PASW Sta-
tistics 18 (SPSS Inc, Chicago, IL) packageswere used. Student's t-test was
used to assess differences between means of continuous variables. The
inﬂuence of mice genotype and pressure overload on myocardial gene
expression was assessed by a two-way ANOVA and, on echocardio-
graphic parameters, by repeated-measures two-wayANOVA. Bonferroni
post hoc test was usedwhen appropriate. Linear regression analysis was
used to detect correlations between gene expression levels. A p value of
b0.05 was considered statistically signiﬁcant.
3. Results
3.1. Myocardial expression of BAMBI in mice and AS patients
Immunoﬂuorescence studies performed in preparations of disso-
ciated mouse cardiac cells reveal that BAMBI immunoreactivity was
present in cardiomyocytes (Fig. 1A) and ﬁbroblasts (Fig. 1B). Fibro-
blasts were identiﬁed based on their positive staining for the mesen-
chymal marker vimentin (Fig. 1C). Immunohistochemical staining
performed in LV sections disclosed the presence of BAMBI immunore-
activity in the myocardium from TAC mice (Fig. 1D) and AS patients
(Fig. 1E). BAMBI immunosignals were detected in cardiomyocytes,
in the vascular wall (Fig. 1D, insert) including the endothelium, and
in ﬁbrotic areas. It is interesting to note that BAMBI immunoreactivity
disclosed a peripheral expression pattern in cardiomyocytes, consis-
tent with its transmembrane localization.
3.2. Parallel LV up-regulation of BAMBI and TGF-β under pressure
overload in humans and mice
We assessed whether cardiac expression of BAMBI was regulated
in response to pressure (Fig. 2). We found that the myocardial
BAMBI mRNA and protein levels of were signiﬁcantly up-regulated
in AS patients and mice subjected to TAC. BAMBI mRNA levels corre-
lated, signiﬁcantly and positively, with the expression of genes
encoding TGF-β1 in AS patients and in mice with TGF-β1, TGF-β2
(r=0.56, pb0.001; n=32) and TGF-β3 (r=0.69, pb0.001; n=32).
Moreover, BAMBI also correlated with the canonical (Smad2) and
non-canonical (TAK1) TGF-β transducers (Fig. 2). Pressure overload is
a hemodynamic condition that is associated with intense myocardial
activation of TGF-β signals in experimental models and patients [7].
Our results demonstrate a coordinated transcription of genes encoding
agonists and antagonists of the TGF-β pathway during pressure
overload. They also suggest that BAMBI could be a transcriptional target
of TGF-βs.
3.3. Transcription of BAMBIwas activated by TGF-β1 in cultured ﬁbroblasts
through Smad and TAK1 pathways
We assessed in cultured ﬁbroblasts whether BAMBI transcription
was under the control of TGF-β signaling (Fig. 3). In primary cardiac ﬁ-
broblasts and NIH-3T3 ﬁbroblasts, the addition of recombinant TGF-β1
to the medium led to a signiﬁcant increase in endogenous BAMBI
mRNA expression. Cell transfection with speciﬁc siRNAs directed
Fig. 1. Immunohistological localization of BAMBI in the LV myocardium. A, B and C: Representative confocal microscopy images showing immunoﬂuorescence staining for BAMBI
(green) in a squash preparation of cardiomyocytes (A) and primary cardiac ﬁbroblasts (B). Fibroblasts were identiﬁed based on their positive staining for the mesenchymal marker
vimentin (C, red). Dapi was used as a nuclear counterstain (blue). D and E: Representative immunoﬂuorescence staining of BAMBI in the mouse LV subjected to aortic constriction
(D) and immunohistochemical (avidin–biotin complex) staining of BAMBI in the LV from AS patients (E). BAMBI immunosignals were detected in cardiomyocytes, in ﬁbrotic areas
and in the vascular wall (insert in D) including the endothelium. Note the marked peripheral staining for BAMBI in cardiomyocytes, consistent with its transmembrane localization.
D′ and E′: Negative controls using PBS instead of the primary antibody.
327A.V. Villar et al. / Biochimica et Biophysica Acta 1832 (2013) 323–335against Smad2/3 or TAK1 attenuated signiﬁcantly the up-regulation of
BAMBI mRNA induced by recombinant TGF-β1 in NIH-3T3 ﬁbroblasts.
The effectiveness of siRNA transfection into the cells was conﬁrmed
by Western blot experiments showing diminished protein levels of
Smad2/3 and TAK1 (Supplemental Fig. S1). Silencing TAK1 also
inhibited the nuclear accumulation of the TAK1-downstream kinases
p38 and JNK.
We further evaluated whether TGF-β signaling is directly involved
in the transcriptional activation of BAMBI in NIH-3T3 ﬁbroblasts
transfected with the BAMBI-Luc promoter and treated with recombi-
nant TGF-β1 (0.3 and 0.6 ng/ml). As shown in Fig. 3, upon adminis-
tration of TGF-β1, the transcriptional activity of BAMBI, reﬂected by
the luciferase signal, increased signiﬁcantly. Co-transfection of the
cells with siRNAs (10 nM) against Smad2/3 or TAK1 signiﬁcantly re-
duced the luciferase activity induced by TGF-β1. Overall, these results es-
tablish a regulatory role for TGF-β signaling, through canonical and
non-canonical pathways, on BAMBI transcriptional activity inﬁbroblasts.
3.4. BAMBI deletion increased the vulnerability of the LV to biomechanical
stress
To determine the functional role of BAMBI in pressure overload-
induced myocardial disease, we studied BAMBI−/− and BAMBI+/+
mice subjected to transverse aortic constriction (TAC). The baseline
and 4-week post-TAC values of echocardiographic parameters are
depicted in Supplemental Table S2. There were no differences be-
tween the two genotypes for the transcoarctational gradients at 1 to
4 weeks following TAC, indicating similar degrees of constriction in
both groups. The heart rate was not signiﬁcantly different between
the BAMBI+/+ and BAMBI−/− groups. The hypertrophy developed
after TAC reached greater values and developed at a more acceleratedpace in BAMBI−/− mice compared with BAMBI+/+, as indicated by
the echocardiographic LV mass (Fig. 4, Supplemental Table S2) and
the gravimetric heart mass indexed to the body weight (BAMBI+/+:
6.20±1.5 mg/g vs. BAMBI−/−: 7.5±1.5 mg/g; pb0.001). Additionally,
during the 4-week follow up after TAC, signiﬁcant differences in the LV
geometry and function were apparent between the BAMBI−/− and
BAMBI+/+ mice. The hearts from the BAMBI−/− mice exhibited more
severe LV dilation, reaching signiﬁcantly higher LVEDds and LVESds
than the BAMBI+/+ mice (Fig. 4 and Supplemental Table S2). The LV
PWTs and IVSTs at baseline and their increases after TAC were similar
in both genotypes (Supplemental Table S2). The LVEF, which reﬂects
the LV short-axis systolic function,wasnegligibly, although signiﬁcantly
reduced by TAC in the BAMBI−/− compared with the BAMBI+/+ mice
(Fig. 4). The LV long-axis systolic function, reﬂected by MAPSE, was
also signiﬁcantly lower in the KO than in the wild type group, either
at baseline or at any time after TAC (Fig. 4). The LV ﬁlling pressure,
reﬂected by the ratio E/E′ (Fig. 4), increased after TAC in both genotypes,
although the rise was signiﬁcantly higher in the BAMBI−/− than in the
BAMBI+/+ mice (Fig. 4).
Overall, these results indicate that BAMBI was up-regulated during
the pressure overload, and that deletion of the gene encoding BAMBI
aggravated pressure overload-induced hemodynamic deterioration.
3.5. BAMBI deletion promoted increased TGF-β signaling in themyocardium
In the next steps, we focused on the mechanisms involved in the
detrimental consequences of BAMBI deletion on heart function
under biomechanical stress. Given that BAMBI functions as a negative
regulator of TGF-βs, we initially assessed whether the release of such
inhibition in BAMBI−/− mice resulted in increased TGF-β signaling.
The nuclear amounts of canonical and non-canonical TGF-β signaling
Fig. 2. Pressure overload induced LV myocardial up-regulation of BAMBI mRNA relative expression (RE, normalized to 18S) in AS patients (A) and mice subjected to transverse aortic
constriction (TAC) (F). RepresentativeWestern blots showingmyocardial overexpression of BAMBI protein in AS patients (B) and TACmice (G). Linear regression analysis, in AS patients
and TACmice, showing the positive correlation between themyocardial mRNA expression of BAMBI and TGF-β1 (C andH), Smad-2 (D and I) and TAK1 (E and J). r=Pearson's correlation
coefﬁcient.
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to the BAMBI+/+ mice at baseline and following TAC. As shown in
Fig. 5, the nuclear protein levels of Smad4 and the downstreamMAP ki-
nases, TAK1, JNK and p38, were signiﬁcantly higher in the myocardiumfrom the shamBAMBI−/−mice compared to the sham BAMBI+/+mice.
Furthermore, when subjected to pressure overload, the myocardium
from the TAC-mice by the 4-week follow up developed a signiﬁcant
up-regulation of genes encoding TGF-β1, TGF-β2, and TGF-β3, with no
Fig. 3. A: Effect of recombinant TGF-β1 on endogenous BAMBI mRNA relative expression (RE, normalized to 18S) in primary cardiac ﬁbroblasts. B: Effect of silencing Smad2/3 and
TAK1 with speciﬁc siRNAs (10 nM) on TGF-β1-induced BAMBI relative expression in NIH-3T3 ﬁbroblasts. C: Effect of recombinant TGF-β1 on luciferase activity and the antagonism
by siRNAs (10 nM) against Smad2/3 and TAK1 in NIH-3T3 cells transfected with the promoter region of BAMBI in a luciferase reporter vector. The results are expressed as relative
luciferase units (RLU). ***pb0.001 vs. TGF-β1+siScr-RNA (ANOVA followed by Bonferroni).
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the nuclear accumulations of Smad4, JNK and p38 were higher in the
TAC-BAMBI−/− mice compared to their TAC-BAMBI+/+ littermatesFig. 4. The echocardiographic dimensional and functional changes induced by pressure over
tion (TAC). IVST: interventricular septum thickness; LVEDd: left ventricular end-diastolic dim
tissue velocity (E′); LVEF: left ventricular ejection fraction; MAPSE: mitral annular plane s
(Repeated-measures two-way ANOVA and Bonferroni post-hoc test).(Fig. 5). These data indicate that BAMBI deletion prompts a gain of
TGF-β canonical and non-canonical signaling with pathophysiological
consequences on LV remodeling under biomechanical stress.load during a 4-week follow-up period in mice subjected to transverse aortic constric-
ension; E/E′: ratio of peak early transmitral ﬂow velocity (E) to peak early myocardial
ystolic excursion. TAC-BAMBI−/− vs. TAC-BAMBI+/+: *pb0.05; **pb0. 01; ***pb0.001
Fig. 5.Myocardial relative expression (RE) levels of mRNAs (normalized to 18S) encoding TGF-β1 (A), TGF-β2 (B), and TGF-β3 (C) in BAMBI+/+ and BAMBI−/− mice, either sham
operated or subjected to transverse aortic constriction (TAC) for 1 or 4 weeks. Pressure overload induced a signiﬁcant up-regulation of TGF-βs, with no signiﬁcant differences be-
tween genotypes (two-way ANOVA). Representative Western blot images showing that the nuclear accumulation of canonical and non-canonical TGF-β signaling mediators Smad4
(D), p38 (E) and JNK (F) were higher in the BAMBI−/− compared to the BAMBI+/+ mice that were either sham operated or subjected to TAC. Loading controls were performed with
the nuclear protein ELK-1.
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in response to pressure overload
The pressure overload induced by TAC caused the up-regulation of
TGF-β target genes that encode extracellular matrix proteins related
to myocardial ﬁbrosis in mice from both genotypes (Fig. 6). Collagen
I, collagen III and ﬁbronectin mRNA expression were signiﬁcantly
higher, and their up-regulation was more accelerated during the
4-week follow-up period in the BAMBI−/− mice compared to the
BAMBI+/+mice. Histological examination of the hearts withMasson's
trichrome staining conﬁrmed that the degree of ﬁbrosis was more se-
vere in the BAMBI−/− mice compared to the BAMBI+/+ mice (Fig. 6
and Supplemental Fig. S2). Densitometric analysis indicated that the
fraction of the LV surface occupied by ﬁbrosis was 3.5±0.9-fold
greater in the BAMBI−/−mice compared to the BAMBI+/+ mice (Sup-
plemental Fig. S2). Western blot analysis conﬁrmed that, following
TAC, ﬁbronectin also reached higher expression in the myocardium
from BAMBI−/− mice (Fig. 6).
Under basal conditions, the myocardial expression of collagen III
mRNA was signiﬁcantly higher in the sham-BAMBI−/−mice compared
to the sham-BAMBI+/+ group (Fig. 6). However, the percentage of the
LV ﬁbrosis area stained by Masson trichrome was negligible (Supple-
mental Fig. S2) and had no consequences on the systolic function of
the sham-BAMBI−/− animals (Fig. 4).
3.7. BAMBI deletion increased myocardial metalloproteinase-2 (MMP-2)
expression and activity in response to pressure overload
The LV transcript levels ofMMP-2 increased following TAC, reaching
signiﬁcantly higher values in BAMBI−/− than in BAMBI+/+ mice
(Fig. 7). Also, gel zymography revealed in both TAC and sham operated
mice a band exhibiting gelatin-degrading activity at 64 kDa molecular
weight, consistent with active MMP-2 (Fig. 7). Following TAC, themyocardium from BAMBI−/− mice displayed signiﬁcantly higher
MMP-2-gelatinase activity compared with their wild type littermates
(Fig. 7). MMP-2 mRNA levels correlated, signiﬁcantly and positively
with the expression of genes encoding TGF-β1 (r=0.43, pb0.01; n=
32), TGF-β2 (r=0.69, pb0.001; n=32) and TGF-β3 (r=0.63, pb0.001;
n=32). MMP-2 also correlated with the non-canonical effector TAK1
(r=0.53, pb0.001; n=32) but it was unrelated to the canonical
(Smads) TGF-β transducers (data not shown). Overall, these results sug-
gest that MMP-2 may be a transcriptional target of TGF-βs.
The mice subjected to TAC displayed, regardless of genotype, a
positive linear correlation between the myocardial transcript levels
of MMP-2 and the LVEDd (r=0.56, p=0.02, n=26), supporting
the notion that, in this scenario, chamber dilation and MMP activity
are linked.
3.8. Treatment with TGF-β neutralizing antibody attenuated pressure
overload-induced cardiac ﬁbrosis in the BAMBI−/− mice
The involvement of TGF-β in the myocardial ﬁbrotic process under
pressure overload has been previously demonstrated by our group
[35] and others [20] using neutralizing monoclonal antibodies against
TGF-β in C57BL6 wild-type mice. Here, we assessed whether TGF-βs
were also responsible for the severe ﬁbrosis displayed by the
BAMBI−/− mice. For this purpose, a series of mice were treated dur-
ing the post-constriction follow-up period with the neutralizing anti-
body anti-TGF-β (0.5 mg every other day, starting on the day of
surgery) or with an IgG1 control. Both the TAC-BAMBI+/+ and
TAC-BAMBI−/− mice treated with the TGF-β-Ab displayed markedly
reduced ﬁbrosis compared to the control mice of each genotype treat-
ed with IgG1, as indicated by Masson's trichrome staining of the heart
sections (Supplemental Fig. S2). These results are consistent with a
relevant participation of TGF-βs in the ﬁbrotic process induced by
pressure overload in both genotypes.
Fig. 6. BAMBI-deﬁcient mice exhibit more severe cardiomyopathy after pressure overload. Relative mRNA expression of genes encoding remodeling-related elements in BAMBI+/+
and BAMBI−/−mice, either sham operated or subjected to aortic arch constriction (TAC). A: Collagen I (Col I); B: Collagen III (Col III); C: Fibronectin 1 (FN-1). The mRNA expressions
were normalized to 18S. Data are expressed as means±SEM. *pb0.05, **pb0.01, ***pb0.001, BAMBI−/− vs. BAMBI+/+ (two-way ANOVA and Bonferroni post-hoc test). The insert
in C shows representative Western blot images of ﬁbronectin protein levels in each experimental group. D: Representative transverse cross-sections of Masson's trichrome-stained
hearts. E: Relative gene expression of extracellular matrix proteins (collagen I, collagen III and ﬁbronectin), the myoﬁbroblast marker α-SMA and the housekeeping protein GAPDH
in primary cardiac ﬁbroblasts cultured in the presence of recombinant TGF-β1 (0.6 ng/ml) for 6 h. The results are expressed as the fold increase in the mRNA levels upon TGF-β1
stimulation in ﬁbroblasts from BAMBI−/− mice compared to BAMBI+/+ mice. **pb0.01, *pb0.05 (Student's t test).
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canonical- and non-canonical effectors
We analyzed the signaling effectors involved in TGF-β1-induced
transcriptional changes in NIH-3T3 ﬁbroblasts by silencing eitherFig. 7. Effects of transverse aortic constriction (TAC) on myocardial relative expression (RE
mined myocardial MMP-2-gelatinase activity (B) in BAMBI+/+ and BAMBI−/− mice. The t
reached signiﬁcantly higher levels in BAMBI−/− compared with BAMBI+/+ mice 4 weeks aft
gelatin lysis in the regions comigrating with MMP-2. Silver staining of a strip obtained from
diagram represents the gelatinase activity determined by optical densitometry of the zymog
Data are expressed as means±SEM. *pb0.05, ***pb0.001, BAMBI−/− vs. BAMBI+/+ (ANOVSmad2/3 or TAK-1 with speciﬁc siRNAs. Cells transiently transfected
with pCol-Luc reporter responded upon stimulation with recombi-
nant TGF-β1 with a signiﬁcant, concentration-dependent increase in
the luciferase activity relative to the vector control, which was antag-
onized by either siSmad2/3 or siTAK1 (Fig. 8).) of mRNA encoding matrix metalloproteinase-2 (MMP-2) (A) and zymography deter-
ranscript levels of MMP-2 and the gelatinase activity dependent of MMP-2 (64 kDa)
er TAC. A: The mRNA expression was normalized to 18S. B: Representative gel showing
the bottom of the gel (below the 37 kDa marker) was used for loading control. The bar
raphic bands. The problem bands were normalized to the control bands in the same gel.
A and Bonferroni post-hoc test).
Fig. 8. A: NIH3T3 ﬁbroblasts transiently transfected with the Col α1-luc reporter responded to recombinant TGF-β1 with a signiﬁcant, concentration-dependent increase in lucif-
erase activity (black circles), which was prevented by silencing Smad2/3 (open circles) and TAK1 (open diamonds) with speciﬁc siRNAs (10 nM). B: Co-transfection of NIH-3T3 cells
with colIagen α1-luc reporter plus BAMBI-ORF (0.2 μg/ml) produced a signiﬁcant reduction in luciferase activity, either basal or induced by TGF-β1. The results are expressed as
luciferase activity relative to the signal of cells transfected with empty vectors (PGL3 in A and pFLC1 in B). Data are the mean±SEM of three independent experiments.
*pb0.05; **pb0.01; ***pb0.001.
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enhanced by BAMBI deletion and attenuated by BAMBI overexpression
To further conﬁrm that TGF-β induces stronger proﬁbrotic re-
sponses in the absence of BAMBI, primary cardiac ﬁbroblasts from
BAMBI−/− and BAMBI+/+ mice were cultured in the presence of re-
combinant TGF-β1. Upon TGF-β1 stimulation, the mRNA expression
levels of ﬁbrosis-related TGF-β-target genes, such as collagen I, colla-
gen III, ﬁbronectin and the myoﬁbroblast marker α-SMA (Fig. 6), andFig. 9. A: Myocardial relative expression (RE) ofmature miR-21 (normalized to RNU6-2). Up-r
higher in BAMBI−/−mice compared to BAMBI+/+ mice (*pb0.05, ***pb0.001, TAC vs. sham; $
nant TGF-β1 induces mature miR-21 overexpression in primary cardiac ﬁbroblasts from BAMB
mice compared to BAMBI+/+mice (***pb0.001, ANOVA followed by Bonferroni). C: In NIH-3T3
ture miR-21, which is prevented by silencing Smad2/3 and TAK1 with speciﬁc siRNAs (10 nM
BAMBI open reading frame (BAMBI-ORF) caused increased expression of BAMBI mRNA (right
induced by TGF-β1 (0.3 ng/ml) was prevented by BAMBI overexpression. Insert: representativ
BAMBI-ORF.miR-21 (Fig. 9), reached signiﬁcantly higher values in ﬁbroblasts lack-
ing BAMBI compared to those from BAMBI+/+ mice.
We next studied whether BAMBI overexpression has opposite ef-
fects on TGF-β1-induced transcription in NIH-3T3 ﬁbroblasts. For this
purpose, cells were co-transfected with BAMBI-pFLC1 and a Col-Luc re-
porter. The overexpression of BAMBI produced by BAMBI-pFLC1 trans-
fection resulted in a signiﬁcant reduction in collagen I transcription, as
reﬂected by the luciferase activity (Fig. 8), at baseline and following
the addition of TGF-β1 to the medium.egulation ofmyocardial miR-21 after transverse aortic constriction (TAC) was signiﬁcantly
pb0.05, BAMBI+/+ vs. BAMBI−/−; two-way ANOVA followed by Bonferroni). B: Recombi-
I+/+ and BAMBI−/−mice. The expression of miR-21 was signiﬁcantly higher in BAMBI−/−
ﬁbroblasts transfectedwith pre-miR21 (10 nM), TGF-β1 induces the up-regulation ofma-
). D: In NIH-3T3 ﬁbroblasts transfected with pre-miR21 (10 nM), co-transfection of the
Y axis) and protein (insert). In parallel, the up-regulation of mature miR-21 (left Y axis)
e Western blot showing increased BAMBI protein expression following transfection with
333A.V. Villar et al. / Biochimica et Biophysica Acta 1832 (2013) 323–3353.11. BAMBI modulates TGF-β-induced miR-21 overexpression
Recent studies have strongly suggested that overexpression of
miR-21 in cardiac ﬁbroblasts is crucially involved in the pro-ﬁbrotic ef-
fects of TGF-β in mice subjected to pressure overload [22] and in AS pa-
tients [24]. Accordingly, we found that miR-21 was up-regulated in the
myocardium from mice of either BAMBI genotype when subjected to
TAC, and that its expression reached signiﬁcantly higher values in
BAMBI−/− compared to BAMBI+/+ mice (Fig. 9). Moreover, primary
cardiac ﬁbroblasts obtained from mice lacking BAMBI responded upon
TGF-β1 stimulation with a signiﬁcantly higher miR-21 overexpression
compared to those obtained from the BAMBI+/+ (Fig. 9). Conversely,
transfection of NIH-3T3 ﬁbroblasts with BAMBI induced BAMBI
overexpression that prevented the up-regulation of mature miR-21 in-
duced by TGF-β1 (Fig. 9).
Silencing of either Smad2/3 or TAK1 with speciﬁc siRNAs prevented
TGF-β1-induced up-regulation ofmaturemiR-21 in NIH-3T3 ﬁbroblasts
(Fig. 9), indicating the involvement of canonical and non-canonical
TGF-β transducers.
4. Discussion
This study for the ﬁrst time demonstrates that the TGF-β
pseudoreceptor BAMBI is expressed in cardiac ﬁbroblasts and
cardiomyocytes. Our central ﬁnding is that BAMBI plays a patho-
physiological role in the modulation of the adverse cardiac remodel-
ing by restraining TGF-β signals in the myocardium, and BAMBI is a
potentially important target for limiting TGF-β activity in the heart
under biomechanical stress. Our characterization of BAMBI functions
in vivo and in cultured cells adds new insights to the complex regu-
lation of TGF-β signaling.
In the last few years, the decoy receptor BAMBI has emerged as a
crucial negative regulator of the TGF-β superfamily signals [26],
with a relevant role for their ﬁne tuning during embryogenesis [36].
Although BAMBI is dispensable for mouse embryo development and
postnatal survival [31], several reports have underlined the impor-
tance of a reliable negative regulation of TGF-β by BAMBI for tissue
homeostasis during adulthood. Aberrant BAMBI expression conveys
TGF-β signaling alterations in different organs and tissues, with rele-
vant pathophysiological implications in processes such as neuropath-
ic pain [31,37], hepatic ﬁbrosis [28], and tumor growth andmetastasis
[29,30,38]. In our study, we identiﬁed that myocardial expression of
BAMBI mRNA is increased in patients with severe AS and mice
subjected to aortic arch constriction. These results support that myo-
cardial BAMBI overexpression is a conserved feature of the pressure
overload in the clinic and in experiments. Moreover, in the stressed
myocardium from AS patients and TAC-mice, the transcript levels of
BAMBI maintained a direct correlation with TGF-β1 and with the
major effectors of its canonical (Smads) and non-canonical (TAK1)
signaling pathways. Such a coordinated spatio-temporal expression
pattern is typically depicted by BAMBI and agonists belonging to the
TGF-β family (BMPs) and their effectors during embryogenesis in a
gene organization termed synexpression, which reﬂects a cooperative
function in the regulation of biological processes. In this context, a key
feature of the BMP synexpression group is the existence of negative
feed-back loops in which the agonists induce the transcriptional activa-
tion of the antagonists [36,39]. In a similar way, in the adult myocardi-
um, TGF-β could promote the expression of its inhibitory counterpart,
BAMBI, setting up an auto-regulatory negative-feedback loop. Our
data in cultured cells support that BAMBI is a direct transcriptional tar-
get of TGF-β signaling and that the mechanism involves canonical
Smad2/3 and non-canonical TAK1 pathways.
In patients with AS, the increased parietal systolic stress induced
by the LV outﬂow obstruction triggers the activation of various signal-
ing cascades [40] that initiate a progressive process of structural and
functional abnormalities, which ultimately result in heart failure[41]. TGF-β has been repeatedly reported to exert a myriad of pleio-
tropic effects on cardiac cells, which underlie the LV remodeling in
AS patients [7,9–11] and animal models [8]. Cardiac tissue ﬁbrosis is
a major feature among the remodeling phenomena and one that
carries with it a bleak clinical prognosis in terms of survival and func-
tional status [42]. Our present results are consistent with the current
understanding that augmented TGF-β signaling results in deleterious
ECM deposition (mainly collagens I and III and ﬁbronectin) which in-
creases myocardial stiffness and, as a consequence, interferes with LV
diastolic and systolic functions [7,42,43]. We propose that the coordi-
nated myocardial expression pattern of BAMBI with TGF-β aims to re-
strain the hypertrophic and ﬁbrogenic signals of this potent cytokine.
In this way, BAMBI could exert a modulation of the turnover of extra-
cellular matrix and sarcomeric components to reach a “balanced” re-
modeling response to the current hemodynamic loading conditions.
Our results in BAMBI−/− and BAMBI+/+ mice subjected to transverse
aortic constriction further support this hypothesis. As expected, the
absence of the inhibitory inﬂuence of BAMBI promptedmore effective
TGF-β cell signaling, both at baseline and after TAC, involving the ca-
nonical (Smad) and non-canonical (TAK1) signaling pathways. Thus,
BAMBI−/− mice, compared to BAMBI+/+ littermates, showed a
higher nuclear expression of Smad4 and MAPKs downstream of
TAK1, such as p38–MAPK and JNK–MAPK, at any pressure load condi-
tion. Consequently, the progression of LV myocardial ﬁbrosis and hy-
pertrophy were exacerbated and accelerated following CAT in
BAMBI−/− mice compared to their BAMBI+/+ littermates.
From a functional point of view, TAC induced a signiﬁcant, albeit
small, reduction in the short-axis systolic function (reﬂected by
LVEF) in BAMBI deﬁcient mice in comparison with the wild type
group. Also, the baseline LV longitudinal systolic function (reﬂected
by MAPSE) was signiﬁcantly poorer in BAMBI−/− mice than in their
wild type littermates and it experienced a signiﬁcant and similar
worsening in both genotypes following TAC. In the clinical scenario,
it is repeatedly observed that even severe myocardial ﬁbrosis does
not result in a signiﬁcant deterioration of the LV short-axis systolic
function as reﬂected by LVEF [42,44]. On the other hand, LV longitudi-
nal systolic function deteriorates early under pressure overload, even
though short-axis function remains relatively preserved [42], because
it is driven by the subendocardial layer of longitudinal muscle ﬁbers
which is most vulnerable to the elevated systolic wall stress and sub-
sequent ﬁbrotic reaction [45]. Many clinical research studies under-
score the importance of myocardial ﬁbrosis to diastolic dysfunction
[42]. LV properties such as passive stiffness, viscoelasticity, distensi-
bility and relaxation, which play a very relevant role in dictating LV
behavior during diastole, are strongly affected by even small changes
in the amount and composition of the extracellular matrix [45]. In
BAMBI−/−mice, the LV ﬁlling pressure (reﬂected by its surrogate var-
iable E/E′) increased signiﬁcantly after TAC and reached higher values
than in wild type animals, in the absence of relevant LVEF deteriora-
tion, which strongly suggests the existence of diastolic dysfunction.
These results are consistent with the more severe ﬁbrosis developed
by BAMBI−/− mice and mirror the ﬁndings in patients with severe
AS that feature a stepwise positive correlation between the severity
of the LV histological ﬁbrosis and E/E′ values [42].
BAMBI−/−mice trend to dilate more severely the LVEDD after TAC
than the wild type reproduces the clinical ﬁnding of greater chamber
dilation in those AS patients with more severe myocardial ﬁbrosis
[42]. Several clinical and experimental studies suggest that an in-
crease in the activity of MMPs underlies LV dilation while MMP inhi-
bition in mice attenuates LV dilation in experimental models of heart
failure [46]. Accordingly, in the present study, MMP-2 was transcrip-
tionally activated following TAC in both BAMBI genotypes and its
mRNA levels correlated signiﬁcantly and positively with the diastolic
dilation of the chamber. In parallel with the LV dilation, the transcript
levels of MMP-2 and its gelatinase activity reached signiﬁcantly
higher values in BAMBI−/− mice than in the wild type group. Since
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through its Smad-mediated canonical signaling, and thereby reduce
ECM turnover [46], it could be presumed that BAMBI deletion and
subsequent TGF-β signaling hyperactivity would exaggerate such an
effect. However, in our study MMP-2 expression correlated positively
and signiﬁcantly with the expression of the three isoforms of TGF-β
and with their non-canonical effector TAK1, which suggests this sig-
naling pathway to activate MMP-2 transcription under our experi-
mental conditions. Else, it has been demonstrated that TGF-β can
activate Smad-independent transcriptional complexes, such as the Ets
family of transcription factors, which would also induce certain MMP
types [47]. Transcriptional activation of MMP-2 by TGF-β may also
occur via an indirect mechanism dependent on miR-21 overexpression
[48]. Thus, as pointed out by Spinale [46], TGF-β might exert dual re-
sponses with respect to MMP transcriptional activity depending on
cell type, local concentration or temporal factors. We suggest that the
absence of BAMBI, by altering the level of TAK1-mediated TGF-β signal-
ing, would favor MMP transcription which is translated into increased
MMP-2 collagenase activity.
Collagen I is a major target gene of TGF-β1 and is responsible for
more than 85% of the total ECM deposition in ﬁbrotic processes. Con-
sistently, NIH-3T3 ﬁbroblasts transiently transfected with the Col
α1-promoter-Luc reporter, upon stimulation with recombinant TGF-β1,
responded with a signiﬁcant increase in luciferase activity, by a mecha-
nism involving Smad2/3 and TAK1. In contrast, when NIH-3T3 cells
were transiently transfected with BAMBI, a signiﬁcant reduction in
TGF-β1-induced Col I-luciferase reporter expression was found, which
underscores the functional antagonistic effect of BAMBI on TGF-β
signaling.
MiRNAs are important regulators of cardiac biology with signiﬁ-
cant roles in diverse cardiac pathological processes. MiR-21 has
been reported as a pro-ﬁbrotic miRNA in many organs, including
heart [21]. In the mouse LV subjected to pressure overload, miR-21
is up-regulated to promote ﬁbroblast survival and growth factor se-
cretion, via down-regulation of Spry1 and subsequent increase of
ERK–MAP kinase activity. The resultant cardiac interstitial ﬁbrosis
and hemodynamic dysfunction can be attenuated by treatment of
mice with an antagomir against miR-21 [22,23]. In AS patients, we
provided evidence supporting that both myocardial and plasmatic
miR-21, acting synergically with TGF-β signal transducers, play a sig-
niﬁcant role in the maladaptive remodeling of the extracellular ma-
trix triggered by pressure overload [24]. Previous studies evidenced
that miR-21 is critically involved in the changes in cellular phenotype
produced by TGF-β proﬁbrotic signals, including ﬁbroblast prolifera-
tion, myoﬁbroblast differentiation and endothelial to mesenchymal
transition [23]. Herein, TAC-induced up-regulation of myocardial ma-
ture miR-21 reached signiﬁcantly higher values in BAMBI−/− com-
pared to BAMBI+/+ mice. Accordingly, the overexpression of miR-21
elicited by recombinant TGF-β1 in primary cardiac ﬁbroblasts
reached higher values when the ﬁbroblasts were obtained from
BAMBI−/− mice. In cultured cells, miR-21 is under the transcriptional
and post-transcriptional control by canonical TGF-β signaling; Smad3 is
crucial for miR-21 transcription [49] and both Smad2 and Smad3 are
able to interact with the p68 RNA helicase of the Drosha microprocessor
complex, promoting the restriction of pri-miR-21 into the precursor
pre-miR-21 [50]. In our study, TGF-β1 induced up-regulation of mature
miR-21 in NIH-3T3 ﬁbroblasts was prevented by silencing Smad2/3 or
TAK1 with speciﬁc siRNAs and by impairing TGF-β signaling via BAMBI
overexpression. Overall, our present results further support that miR-21
biogenesis in ﬁbroblasts is dependent on TGF-β1 signaling, through
both canonical Smad-dependent and non-canonical TAK1-dependent
pathways, and BAMBI functions as a negative regulator of such TGF-β
function.
In conclusion, our ﬁndings in AS patients, experimental animals
and cultured cells constitute the ﬁrst evidence identifying the TGF-β
pseudoreceptor BAMBI as a new player, and potential target fortherapy, in remodeling of the heart under pressure overload. We pro-
pose that myocardial expression of BAMBI is regulated in a coordinated
manner with TGF-βs to restrain the hypertrophic and ﬁbrogenic
signaling of these cytokines through a negative feedback loop. In
this way, BAMBI could modulate the turnover of extracellular matrix
components to reach a robust remodeling response “balanced” to the
current hemodynamic loading condition. Alterations in BAMBI may
play a role in the pathophysiology of myocardial ﬁbrosis, and manip-
ulation of BAMBI might confer disease-speciﬁc therapeutic beneﬁts.
Further experimental and clinical studies are warranted to clarify
whether such approaches may offer new therapeutic opportunities
for the palliation of pathological myocardial ﬁbrosis.
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